Clinical trial · Interventional
Collaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication
Deploying and Evaluating a Technology Based System to Help People Adhere to Long Term Medications
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to learn about the impact of an integrated medication monitoring system in breast cancer survivors aged 21-70 who are prescribed endocrine therapy. The main question it aims to address is: Does the integrated medication monitoring system improve medication adherence among breast cancer survivors when used over a six-month period? Fifteen English-speaking breast cancer survivors who meet the inclusion criteria will use a combination of smartphone-based ecological momentary assessments, a medication event monitoring system (Wisepill), and a wearable sensor (Fitbit). After 2 months, participants will be provided personalized content to facilitate medication adherence through an app (Digital Trails) and through WisePill. Participants will complete online surveys at baseline, 3 months, and 6 months to assess their experiences and adherence.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | — | UNRESOLVED | — |
| Breast Cancer Survivor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| integrated medication monitoring (MM) system | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- integrated medication monitoring system
- description
- The single-arm intervention design of this study focuses on delivering a comprehensive integrated medication monitoring system to a cohort of breast cancer survivors. The system will analyze data collected from EMAs, MEMS, and Fitbit sensors to identify participants at risk of nonadherence. Based on this risk assessment, personalized interventions will be delivered through the Digital Trails app, which may include reminders for medication intake, among others.
- interventionNames
- Device: integrated medication monitoring (MM) system
Primary outcomes (26)
- measure
- Wisepill MEMS Sensor data collection
- timeFrame
- From enrollment to the end of study at 6 months
- description
- Participants will be asked to put their endocrine therapy medication in the Wisepill device and will be asked to open the Wisepill when taking their medicine daily for six months
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * are English-speaking and reading; * are between ages 21 and 70 years; * are diagnosed with stage 0-3 breast cancer in the past 5 years; * have completed all surgery, radiation, and chemotherapy, except endocrine therapy; * are prescribed endocrine therapy; * do not have a physical impairment that would prevent them from using the MM system; * are able to provide informed consent; * are willing and able to use the MM system for 6 months; * have an Iphone or Android phone.
References
Publications (0)
Data not yet available